10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds

8. Erasca Inc. (NASDAQ:ERAS)

Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.

On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck. The collaboration is aimed at facilitating the AURORAS-1 clinical proof-of-concept research. This research thoroughly assesses the exclusive pan-RAS molecular glue ERAS-0015 in conjunction with Merck’s anti-PD-1 treatment, KEYTRUDA, for patients fighting RAS-mutant solid tumors.

As per the arrangement, Merck will supply its therapeutic drug free of cost to the clinical-stage oncology firm, which will act as the principal research sponsor. Preclinical evidence shows that RAS mutations actively promote an immunosuppressive environment before this clinical development. Management hopes to overcome these biological hurdles and drive highly durable tumor responses by carefully combining ERAS-0015 with PD-1 blocking treatments.

With approximately 2.7 million global diagnoses of RAS-mutated tumors annually, the medical landscape indicates persistent challenges regarding broad treatment efficacy and drug resistance. Hence, in order to significantly enhance therapy results and substantially prevent the development of treatment resistance, the company intends to utilize this tailored combination.

Erasca Inc. (NASDAQ:ERAS) is a clinical-stage precision oncology company that focuses on developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The product pipeline includes ERAS-0015, ERAS-4001, and ERAS-12. It has established licensing agreements with multiple pharmaceutical partners for the development of additional therapeutic compounds. These include naporafenib, ERAS-601, and ERAS-007.